L

Lipocine
D

LPCN

3.40000
USD
0.00
(0.00%)
مغلق
حجم التداول
291
الربح لكل سهم
-2
العائد الربحي
-
P/E
-5
حجم السوق
18,191,210
أصول ذات صلة
A
AMRN
0.000
(0.00%)
10.990 USD
C
CRBP
0.26000
(3.45%)
7.79000 USD
M
MNOV
-0.02000
(-1.31%)
1.51000 USD
المزيد
الأخبار المقالات

العنوان: Lipocine

القطاع: Healthcare
الصناعة: Biotechnology
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.